State:
Texas
Category:
Pharmaceuticals & Supplements
Asking Price:
-
Revenue:
-
Company Overview
PRIME exits and American HealthCare Capital are pleased to introduce a clinical-stage biopharmaceutical business with a novel, patented, small-molecule therapeutic agent for brain cancers. The agent selectively targets and inhibits a transcription factor that is highly expressed in glioblastomas and other tumors of the brain. In tumor cell-based and animal models of glioblastoma, the agent is effective in selectively killing tumor cells, alone and in combination with other targeted therapies. The drug is orally available and has been shown to attain therapeutically relevant concentrations in the brain tissue of non-human primates. The key value drivers for this therapy include:
Asking Price
The price and structure of any transaction are to be determined.
Inquire About This Listing:
In order to learn more about our listing, you must:
1. Complete a Buyer Profile:
This profile will be used to pre-qualify buyers and determine whether we can share additional details about our listings. If you have already completed a Buyer Profile, disregard.
YOU ONLY NEED TO COMPLETE A BUYER PROFILE ONCE.
2. Sign NDA with Listing Code:
To learn more about this listing, you must sign an NDA. When completing the NDA, you will need to copy the exact LISTING CODE and LISTING TITLE.
Listing Code:
TXPH1B
Listing Title:
Clinical-Stage Biopharma with a Novel, Targeted Therapy for Brain Tumors
Heading 4
Need to learn more before Signing an NDA- Contact the Lead Advisor For This Mandate
